NEW YORK (GenomeWeb News) – Sample prep firm IntegenX today said it has been awarded a $2.8 million contract by the US Department of Defense to develop a system for the rapid detection and identification of genetically engineered bacteria and viruses.
The contract from DoD's Defense Threat Reduction Agency is the first phase of a possible 22-month, $14.8 million contract, the Pleasanton, Calif.-based company said in a statement. The integrated sample-to-sequence system it is developing will also be used to detect and identify medically relevant bacteria and viruses, as well as emerging pathogens.
The company will use its Universal Sample Preparation Module to purify DNA from pathogen targets contained in complex matrices. The purified material will be presented to an IntegenX library construction module, then an amplification module, and finally a next-generation sequencing module. The USPM was developed with an earlier DOD contract.
IntegenX plans to apply its Move technology to integrate the complete workflow of the ISS system. The system will be less than three cubic feet, it said.
Formerly called Microchip Biotechnologies, IntegenX manufactures automated DNA- and RNA-based sample-preparation systems for life sciences, applied sciences, and diagnostics markets.